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OBJECTIVES: Progressive multifocal leukoencephalopathy (PML) is an infrequent
but serious adverse event associatedwith natalizumab in the treatment of patients
with relapsing-remittingmultiple sclerosis (RRMS). The objective is to evaluate the
risks and benefits of natalizumab treatment across three PML risk sub-groups
against comparator agent interferon- and no treatment. METHODS: The risk-
benefit analysis was conducted using an adaptation of the original natalizumab
model submitted to the National Institute for Health and Clinical Excellence that
simulates natural disease progression and potential treatment impact on out-
comes. A PML risk stratification component was incorporated to define PML risk by
anti-JC virus (JCV) antibody status, previous immunosuppressant (IS) history, and
duration of exposure to natalizumab therapy. A disutility score was applied to PML
and post-PML states, as well as disease states defined by EDSS scores. RESULTS:
Over a 20-year time horizon, treating anti-JCV antibody negative patients with
natalizumab resulted in a total of 6.49 quality-adjusted-life-years (QALYs) per pa-
tient. Treatment with natalizumab in the anti-JCV antibody positive sub-groups,
with and without previous IS history resulted in 6.27 and 6.43 QALYs per patient,
respectively. Interferon- treatment resulted in 6.05 QALYs per patient across all
PML risk groups, whereas no treatment led to 5.82 QALYs per patient. In the highest
risk group (anti-JCV antibody positive with prior IS use), utility decrement due to
PMLwas small compared to the lowest risk anti-JCV antibody negative group (0.22),
and overall QALYs were higher than interferon- and no treatment. When consid-
ering the overall RRMS patient population, the risk of PML associated with natali-
zumab had to be more than 10.43 times higher in order to result in equivalent
QALYs with interferon-. CONCLUSIONS: The risk of PML associated with natali-
zumab treatment is offset by the benefit of natalizumab across all patient groups
compared to interferon- and no treatment.
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OBJECTIVES: The development of dyskinesia in Parkinson’s disease (PD) patients
may be associated with pulsatile stimulation of dopamine receptors, especially
when using short-acting dopaminergic agents such as levodopa. Adjunctive ther-
apy to levodopa with dopamine agonists may increase the risk of dyskinesia. This
study quantitatively assessed the short-term incidence of dyskinesia in patients
with advanced PDwhen treatedwith rotigotine transdermal patch (RTG) compared
with ropinirole (ROP) and pramipexole (PPX) immediate-release (IR) and extended-
release (ER). METHODS: A systematic review of randomized controlled compara-
tive trials of RTG, ROP, PPX and placebo (PBO) on a background of levodopa therapy
in advanced PD patients was performed, followed by a network meta-analysis.
Trials published up to September 2011 were included. Incidence of dyskinesia was
assigned as reported in each study. Study-level relative treatment effects were
combined using both random-effect (base case) and fixed-effectmodels (sensitivity
analysis) within a Bayesian framework using Markov Chain Monte Carlo methods
in WinBUGS. RESULTS: Sisteen trials and 4446 patients were incorporated in the
meta-analysis, which included 20 direct pair-wise comparisons. Patient character-
istics were similar in terms of mean age at baseline, disease duration and severity
(UPDRS III); however, average levodopa dosage differed across studies (range 272.9-
843.4 mg/day). Under the base case assumption, odds of dyskinesia occurrence
were comparable across dopamine agonists; odds numerically favored RTG over
ROP-IR (OR: 0.70 [95% CI: 0.31, 1.59]), ROP-ER (0.33 [0.09, 1.15]) and PPX-IR (0.86 [0.49,
1.58]), but not PPX-ER (1.02 [0.42, 2.43]). The sensitivity analysis suggested that
patients receiving RTGwere estimated to experience fewer dyskinesias than those
receiving ROP-ER (0.32 [0.11, 0.88]). CONCLUSIONS: This meta-analysis suggests
that in levodopa-treated patientswith advanced PD, dopamine agonists were com-
parable in terms of short-term odds of experiencing dyskinesia, with a numerical
trend favoring RTG over ROP-ER. Further large-scale, confirmatory randomized
clinical trials are required.
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OFTEN CONSIDERED FOR TREATMENT-EXPERIENCED PATIENTS WITH
RELAPSING-REMITTING MULTIPLE SCLEROSIS
Allen FL1, Osei-assibey G1, Arnold R2, Deniz B2
1Abacus International, Bicester, Oxfordshire, UK, 2Biogen Idec, Weston, MA, USA
OBJECTIVES: Relapsing-remitting multiple sclerosis (RRMS) is the most common
form of MS and is characterised by inflammatory episodes in the brain followed by
periods of remission. Damage caused by relapses accumulates over time andmany
patients will develop some form of permanent disability after 10 years. Natali-
zumab 300mg, fingolimod 0.5mg and INF-1a 44mcg are typically considered for
treatment-experienced patients with RRMS. This meta-analysis aimed to assess
the efficacy of natalizumab versus other potential treatments for RRMS.METHODS:
Electronic searches of Medline, Embase and the Cochrane library were undertaken
to identify potential studies conducted in adults with RRMS treated with natali-
zumab, fingolimod or INF-1a. Direct meta-analysis was conducted in STATA ver-
sion 12 using the metan package. Indirect comparisons between treatments via
common comparators were made using the Bucher method. RESULTS: Out of 2512
records obtained from systematic searches, forty studies were included in the final
data set. Analysis of evidence suggested that patients treated with natalizumab
were twice as likely to remain free from disease activity (ie free from both clinical
and radiological activity) at 24months comparedwith fingolimod (OR2.05, 95%CI:
1.127, 3.735). Progression of disability (i.e. increase in EDSS score) was lower in
patients treated with natalizumab compared with fingolimod (mean difference in
EDSS score change -0.69, 95% CI: -0.882,-0.498). Patients treatedwith natalizumab
had a 50% lower chance of relapse per year comparedwith INF-1a (OR0.5, 95%CI:
0.391, 0.640). Likewise, patients receiving fingolimod were less likely to have a
relapse in a year comparedwith INF-1a (OR0.64, 95% CI: 0.477, 0.867). Analysis of
additional outcomes based on limited data, showed directional favour towards
natalizumab compared with fingolimod and INFb-1a without reaching statistical
significance.CONCLUSIONS:Comparedwith fingolimod and IFNb-1a, natalizumab
was shown to be a more effective treatment alternative for RRMS patients in this
analysis.
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OBJECTIVES: Those non-benzodiazepine hypnotics (Z-drugs) were introduced for
the short-term management of insomnia due to its advantage of favorable safety
profiles. It is inconclusive about its benefits of long-term use and risks of depen-
dence concerning Z-drugs. This study was to examine the trends of Z-drugs pre-
scriptions stratified by elderly and non-elderly adult populations across times in
Taiwan.METHODS:We conducted a secondary data analysis using 2000 and 2005
Longitudinal Health Insurance Database (2 million random samples). During the
observation period (2003 to 2009), we defined adult outpatient users as those NHI
adult beneficiaries (aged 18 year-old) ever made outpatient visits and Z-drug
users as those ever prescribed with Z-drugs (zolpidem, zopiclone and zaleplon) in
each year. The prescription prevalence rate of Z-drugs, its average number of de-
fined daily dose (DDD) and prescriber specialties were stratified by age (elderly vs.
non-elderly) and gender and compared across years. RESULTS: Among adult out-
patient users, the prescription prevalence rate of Z-drugs was increased from 2003
to 2005, decreased in 2006 but maintained from 2007 to 2009. Female and non-
elderly patients were predominant (all about 61%) across years. The average DDD
within one year were increased over 7-year period (exception in 2006) and that
among elderly users was always higher than non-elderly users. There were up to
8.3% of Z-drug users prescribed with over 365 DDD yearly (9.0% in elderly group).
While 36% were prescribed by more than two specialties, the top 4 prescriber
specialties were general/family medicine, internal medicine, psychiatry and neu-
rology, regardless of age groups and years. CONCLUSIONS: Except in 2006, the
Z-drugs prescription was gradually increased but maintained from 2003 to 2009 in
Taiwan. Those common prescribers of Z-drugs should be warrant about its long-
term uses for whole year, especially among the elderly.
NEUROLOGICAL DISORDERS – Cost Studies
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BACKGROUND: Multiple sclerosis (MS) is a neurodegenerative disease associated
with long-term disability and significant social economic impact. Available first-
line diseasemodifying treatments for MS (interferons and glatiramer acetate) have
moderate efficacy and must be administered in daily or weekly injections. The
introduction of fingolimod, a newmolecule which superior efficacy in reducing MS
relapses compared to interferon-beta 1a im justifies a budget impact analysis from
the Colombian health system perspective. OBJECTIVES: To develop a budget im-
pact analysis, for years 2012 to 2016, of the introduction of fingolimod in the Co-
lombian health system, for the treatment of remitting relapsing multiple sclerosis
(RRMS). METHODS: Using the perspective of the Colombian health system, we
designed a budget impact model to compare costs of illness with and without the
introduction of fingolimod for patients with RRMS. Clinical data and prevalence
were obtained from published literature, costs were collected from local sources. A
Monte Carlo simulationwas performed as part of the sensitivity analysis. Exchange
rate usedwas 1.786 Colombian pesos per US dollar (Jun 2011). No discount rate was
used. RESULTS: Total annual net costs (from 2012 to 2016) for the scenario without
fingolimod were, in million USD, $11.44, $12.16, $12.75, $13.47, and $14.18. In the
fingolimod scenario net costs were: $11.46, $12.23, $12.83, $13.59 and $14.41. On the
other hand, fingolimod was associated with 91 relapses averted in this five year
period. Monte Carlo simulation did not show significant differences in costs be-
tween both scenarios. CONCLUSIONS: Under these assumptions, the introduction
of fingolimod in the Colombian health care system does not imply a significant
budget impact but represents an important reduction in the number of relapses.
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BUDGET IMPACT ANALYSIS OF ANTIEPILEPTIC DRUGS IN THE TREATMENT OF
LENNOX-GASTAUT SYNDROME
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OBJECTIVES: Lennox-Gastaut syndrome (LGS) is a debilitating form of epilepsy
characterized by developmental disorders and high frequency of drop attacks that
are often refractory to antiepileptic drug (AED) therapy. Clobazamwas approved by
the FDA in October 2011 for adjunctive treatment of seizures associated with LGS.
Wedeveloped amodel to compare the budget impact of adding clobazam to anAED
portfolio containing topiramate, lamotrigine, and rufinamide in a hypothetical
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100,000-member health care plan. METHODS: Patient characteristics and AED ef-
ficacy (decrease from baseline in frequency of drop seizures) were modeled with
clinical trial data. Medical costswere derived fromadministrative claims data from
a large US managed health care plan affiliated with OptumInsight, with the as-
sumption that 2.3% of drop seizures required medical care. Budget impact was
measured over 2 years. Results were expressed as overall difference in costs (sei-
zure and pharmacy) to a health plan, and cost permember permonth (PMPM) after
the addition of clobazam. Alternative scenario analyseswere performed.RESULTS:
With the assumption that 0.04 % of the plan population had LGS, addition of clo-
bazam to the formulary resulted in cost savings of $78,600 in Year 1 and $104,000 in
Year 2, corresponding to savings of $0.07 and $0.09 PMPM, respectively. Alternative
analyses with lower seizure rates upon discontinuation or greater long-term effi-
cacy for lamotrigine and topiramate did not substantially alter the conclusion.
Assumption that fewer drop seizures require medical care resulted in a modest
cost increase with clobazam, suggesting that medically attended drop seizures are
a primary driver of costs for LGS patients. CONCLUSIONS:Medically attended drop
seizures are a major cost driver for LGS patients. Our results demonstrate that
adding clobazam to a health care plan formulary can have a positive overall budget
impact through a decrease in medical costs associated with drop seizures.
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OBJECTIVES: To develop a budget impact (BI) and cost-effectiveness (CE) model to
determine the effect of introducing the recently approved once-daily gabapentin
(Gralise™; G-QD) into the existing market of postherpetic neuralgia (PHN)
treatments.METHODS: The BImodel is based on estimated US. PHN incidence and
captures treatment costs from initiation of PHN therapy through sixmonths. Initial
treatments included G-QD, gabapentin TID, and pregabalin. After assessment at 10
weeks, patients could remain on initial monotherapy, or add, switch, or discon-
tinue PHN treatments. Post-assessment therapies also included lidocaine patch
and opioids. Clinical and epidemiological data sources consisted of clinical trial
data, US census data, and published literature. The US payer perspective model
includes direct medical costs (in 2010 US dollars) including pharmacy, physician
visits, and treatment of adverse events. Discounting was excluded due to the short
timeframe. Drugs were priced at wholesale average cost (WAC). Other pricing fac-
tors were co-pays and rebates. Cost sources included proprietary standardized
databases, Medicare fee schedules, and published literature. The CE analysis was
based on a hypothetical 1000-patient cohort. Patientswith andwithout pain reduc-
tion were determined from clinical trial data; outcomes were quality adjusted
based on published PHN utility data for pain and adverse events. Costs were taken
from the BI analysis. RESULTS: For 34,183 PHN patients, the addition of G-QD
decreased the total cost budget by $12,230 (-0.04%). While the pharmacy budget
increased by $299,547 (1.34%), the non-pharmacy budget decreased by $311,777
(-3.06%). In the CE analysis, the incremental cost per quality-adjusted life year was
$31,257 for G-QD versus gabapentin TID, and G-QD dominated pregabalin. Sensi-
tivity analysis demonstrated stable results. CONCLUSIONS: The budget impact of
introducing G-QD to the market is small when considering only pharmacy costs,
but may be cost saving when non-pharmacy costs are included. G-QD is cost-
effective versus other initial PHN treatments.
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OBJECTIVES: Polyethylene glycol-conjugated (PEGylated) therapies are commonly
used to treat patients with anemia, neutropenia, and viral hepatitis. While no
PEGylated drugs are currently approved for the treatment of multiple sclerosis
(MS), a PEGylated formulation of interferon beta-1a is being developed for relaps-
ing-remitting MS treatment. The goal of this study was to identify the economic
benefits of PEGylated drugs currently available in other disease areas.METHODS:A
comprehensive search of the medical literature was conducted using PubMed/
MEDLINE, article links, and supplemental searches. Inclusion criteria included Eng-
lish language, publication date between 1985 and 2010, prospective or retrospective
study design, and cost or cost-effectiveness studies comparing PEGylated drugs
with their non-PEGylated counterparts in the same therapeutic area. All costs were
adjusted to 2010 US dollars for reporting. RESULTS: Thirty-seven published articles
reporting data from 11 countries in 12 therapeutic areas were reviewed, including
studies on pegfilgrastim, liposomal PEGylated doxyrubicin, peginterferon alfa 2a
and 2b, pegaspargase, and PEGylated epoetin. Twelve studies showed some cost
offsets for 6 PEGylated drugs, with 4 of the drugs reducing administration costs.
Other offset costs included those for adverse event treatment, disease complica-
tions, and inpatient/outpatient treatment. Nineteen of the 35 studies considering
total treatment costs showed total cost savingswith 3 of 5 PEGylated drugs, ranging
up to $7743 per patients annually.With 4 PEGylated drugs, 17 of 18 studies reported
incremental cost-effectiveness ratios below $50,000 per quality-adjusted life-year.
CONCLUSIONS: PEGylated drugs are reported to reduce patient health resource use
and costs, including costs associatedwith drug administration and adverse events.
Since multiple studies have demonstrated that PEGylated drugs are more cost-
effective than their non-PEGylated counterparts, PEGylated interferon beta-1amay
offer similar economic benefits to payers and health care systems.
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OBJECTIVES: Little US data are available on the costs of HD, a debilitating disease
marked by motor/cognitive/psychiatric impairment worsening through distinct
disease stages. Our study aimed to quantify the direct health care costs (andmajor
cost drivers) among HD patients by disease stage in commercial (C) versus Medic-
aid (M) databases.METHODS: Health care utilization/cost data (pharmacy, outpa-
tient, inpatient) were obtained for HD patients (ICD-9-CM 333.4) from Thomson
Reuters’ MarketScan M/C 2002-2009 databases. Patients were classified by disease
stage (early/middle/late) via a hierarchical assessment ofmarkers of disease sever-
ity, whichwas confirmed by literature review/key opinion leader input. Health care
utilization/costs were measured over the follow-up time of each patient with total
costs/patient/stage annualized using a patient-year cost approach. RESULTS: A
total of 1272 HD patients (752/520 C/M) were included for this study. The mean age
was similar between the two populations (C: 48.5 years (SD 13.3); M: 49.3 years (SD
17.2)) with slightly higher female representation in the M population (60.8% vs.
54.1%). A fairly even C patient distribution by stage was noted (30.5%/35.5%/34.0%;
early/middle/late). However, most (74.0%) M HD patients were classified as late
stage. Themean total annualized cost per patient varied in both populations (early:
C - $4,947 (SD $6,040), M - $3,257 (SD, $5,670); middle: C - $15,066 (SD $21,722), M -
$12,330 (SD $16,986); late: C - $22,582 (SD $39,028), M - $37,495 (SD $27,111)). Outpa-
tient costs were the primary health care cost component, except for M early stage
(outpatient: early: C – 45.8%; middle: C – 48.2%, M – 66.4%; late: C – 41.5%, M – 78.9%;
inpatient: early: M - 37.7%). Nursing home costs contributed to 54.6% of M but only
4.6% of C total late stage costs. CONCLUSIONS: HD direct health care costs in-
creasedwith disease progression. Late stageM patients had higher costs than their
C counterparts, due to nursing home costs.
PND10
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OBJECTIVES: To describe diagnosis codes, frequency and cost of multiple sclerosis
(MS)-related hospital and emergency room (ER) utilization.METHODS:Two cohorts
of MS-diagnosed patients aged 18-64 years were selected from a national managed
care database: 1) longitudinal cohort: patients with 12 months pre/post eligibility
around first MS diagnosis occurring January 1, 2002 to July 30, 2010, and 2) cross-
sectional cohort: patients with an MS diagnosis in 2010. MS-related [multiple scle-
rosis (ICD-9-CM340.XX), other demyelinating CNS disease (ICD-9-CM341.XX),
and a group of symptom-related codes] hospitalizations and ER visits were evalu-
ated. Rehabilitation (ICD-9-CMV57.89) was included based on qualitative review
of codes. Mean number and cost per patient, adjusted to $US 2010, were described.
RESULTS:Therewere 31,905 patients in the longitudinal cohort and 32,845 patients
in the cross-sectional cohort. In the longitudinal cohort, 18.5% had a post-index
hospitalization (any cause) with 5.2% being MS-related (340.XX: 3.2%; 341.XX: 0.4%;
rehabilitation: 0.8%; and symptom-related: 1.1%). Mean number and cost (SD) of an
MS-related hospitalization were 1.19 (0.55) and $14,358 ($32,356), respectively. In
addition, 31.4% of patients experienced a post-index ER visit with 6.9% being MS-
related (340.XX: 2.9%; 341.XX: 0.2%; symptom-related: 4.7%).Meannumber and cost
(SD) of an MS-related ER visit were 1.23 (0.78) and $573 ($816), respectively. In the
cross-sectional cohort, 12.5% had a hospitalization (any cause) with 3.7% being
MS-related (340.XX: 2.1%; 341.XX: 0.2%; rehabilitation: 1.1%; and symptom-related:
0.7%). Mean number and cost (SD) of an MS-related hospitalization were 1.32 (0.78)
and $16,213 ($25,394), respectively. In addition, 27.3% of patients experienced an ER
visit with 6.4% beingMS-related (340.XX: 2.6%; 341.XX: 0.1%; and symptom-related:
4.5%).Meannumber and cost (SD) of anMS-related ER visitwere 1.37 (0.89) and $682
($825), respectively. CONCLUSIONS: Costs for hospitalization and ER visits among
MS patients were substantial. Inclusion of rehabilitation and symptom-related
codes can account for an under-recognized proportion of expenditures.
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OBJECTIVES: Cervical dystonia (CD), or spasmodic torticollis (333.83), is the most
common adult-onset focal dystonia and is associated with significant pain and
disability. The quality of life burden of CD has been well documented; however,
very limited information exists regarding the economic burden of CD. This study
aims to quantify the average per-patient cost of CD health care resource use using
baseline data from the CD Patient Registry for the Observation of Onabotulinum-
toxinA Efficacy (CD PROBE), a large ongoing registry. METHODS: At baseline, par-
ticipants reported use of specific health care resources over the preceding 6
months, including visits to a primary care provider, neurologist, physiatrist, phys-
ical or occupational therapist, neurosurgeon, alternative care provider, chiroprac-
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